Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Study:

A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Rationale:

n/a

Purpose:

Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening. The purpose of this study is to determine if a daily injection of a blood-thinner, dalteparin, for 12 weeks can safely and effectively reduce the frequency of blood clots. Dalteparin is currently approved for prevention of blood clots following surgery and in hospitalized patients but not specifically for cancer outpatients.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Venous Thromboembolism
Pulmonary Embolism
Drug: dalteparin injection Phase 3

Verified by University of Rochester September, 2013

Sponsored by: University of Rochester
Information provided by: University of Rochester
ClinicalTrials.gov identifier: NCT00876915

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Cleveland Clinic
Cleveland, Ohio 44195
United States

Charles W. Francis, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site